NO20014770L - Assosiasjon av NO-syntase-inhibitor(er) og metabolske antioksydanter - Google Patents

Assosiasjon av NO-syntase-inhibitor(er) og metabolske antioksydanter

Info

Publication number
NO20014770L
NO20014770L NO20014770A NO20014770A NO20014770L NO 20014770 L NO20014770 L NO 20014770L NO 20014770 A NO20014770 A NO 20014770A NO 20014770 A NO20014770 A NO 20014770A NO 20014770 L NO20014770 L NO 20014770L
Authority
NO
Norway
Prior art keywords
association
synthase inhibitor
metabolic
antioxidants
metabolic antioxidants
Prior art date
Application number
NO20014770A
Other languages
English (en)
Other versions
NO20014770D0 (no
Inventor
Michel Auguet
Jeremiah Harnett
Pierre-Etienne Cha Lassauniere
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of NO20014770D0 publication Critical patent/NO20014770D0/no
Publication of NO20014770L publication Critical patent/NO20014770L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
NO20014770A 1999-04-02 2001-10-01 Assosiasjon av NO-syntase-inhibitor(er) og metabolske antioksydanter NO20014770L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9904134A FR2791571B1 (fr) 1999-04-02 1999-04-02 Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
PCT/FR2000/000812 WO2000059448A2 (fr) 1999-04-02 2000-03-31 Association d'inhibiteur(s) de no synthase et d'antioxydant(s) metabolique(s)

Publications (2)

Publication Number Publication Date
NO20014770D0 NO20014770D0 (no) 2001-10-01
NO20014770L true NO20014770L (no) 2001-11-23

Family

ID=9543945

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014770A NO20014770L (no) 1999-04-02 2001-10-01 Assosiasjon av NO-syntase-inhibitor(er) og metabolske antioksydanter

Country Status (9)

Country Link
EP (1) EP1169005A2 (no)
JP (1) JP2002541077A (no)
AR (1) AR023219A1 (no)
AU (1) AU3663700A (no)
CA (1) CA2365500A1 (no)
FR (1) FR2791571B1 (no)
MY (1) MY133230A (no)
NO (1) NO20014770L (no)
WO (1) WO2000059448A2 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2816509B1 (fr) * 2000-11-15 2004-02-06 Sod Conseils Rech Applic Association d'inhibiteurs de calpaine et de piegeurs des formes reactives de l'oxygene
US6476073B1 (en) * 2000-11-21 2002-11-05 Arthur Vanmoor Method of treating a hangover by enhancing the effectiveness of the human immune system
CA2515929C (en) * 2003-02-14 2013-11-19 Children's Hospital & Research Center At Oakland Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
DK1754478T3 (da) 2005-08-04 2009-05-04 Encrypta Gmbh Flydende sammensætning omfattende arginin og alfa-liponsyre og anvendelse heraf til forbedring af den seksuelle funktion
US20110213021A1 (en) * 2008-03-04 2011-09-01 Indigene Pharmaceuticals, Inc. Compositions and methods for treating nos-associated diseases
JP2011521908A (ja) * 2008-05-09 2011-07-28 デューク ユニバーシティ チオレドキシンが細胞における一酸化窒素放出を調節するという知見に基づく疾患の治療法
TWI592156B (zh) * 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
US20150025147A1 (en) * 2012-03-02 2015-01-22 Kyowa Hakko Bio Co., Ltd Enhancer for eating activity and/or gastrointestinal activity
US20150174160A1 (en) * 2012-07-03 2015-06-25 Jay Pravda Methods for treating, diagnosing and/or monitoring progression of oxo associated states

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4630M (no) * 1965-06-09 1966-11-28
ZA716628B (en) * 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
US5091180A (en) * 1987-11-20 1992-02-25 Administrators Of The Tulane Educational Fund Protection against rhabdomyolysis-induced nephrotoxicity
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5852058A (en) * 1993-06-11 1998-12-22 The Board Of Trustees Of The Leland Stanford Junior University Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
GB9404400D0 (en) * 1994-03-07 1994-04-20 Wood Pauline J Potentiation of bioreductive agents
DE4420102A1 (de) * 1994-06-09 1995-12-14 Asta Medica Ag Arzneimittelkombinationen aus alpha-Liponsäure und herz-kreislaufaktiven Substanzen
WO1996030012A1 (en) * 1995-03-24 1996-10-03 Defeudis Francis V Methods for treating conditions associated with excess nitric oxide
US5951990A (en) * 1995-05-15 1999-09-14 Avon Products, Inc. Ascorbyl-phosphoryl-cholesterol
EP0891719A1 (en) * 1997-07-14 1999-01-20 N.V. Nutricia Nutritional composition containing methionine
WO1999006040A1 (en) * 1997-08-04 1999-02-11 Berry Christopher J Method of treating disease using a tocotrienol and alpha-lipoic acid or derivatives or an ester thereof
EP1065931A4 (en) * 1998-04-02 2006-10-11 Avicena Group Inc COMPOSITIONS CONTAINING CREATINE COMBINED WITH A SECOND AGENT

Also Published As

Publication number Publication date
FR2791571A1 (fr) 2000-10-06
WO2000059448A2 (fr) 2000-10-12
MY133230A (en) 2007-10-31
NO20014770D0 (no) 2001-10-01
FR2791571B1 (fr) 2002-10-04
WO2000059448A3 (fr) 2001-03-08
JP2002541077A (ja) 2002-12-03
AU3663700A (en) 2000-10-23
CA2365500A1 (fr) 2000-10-12
AR023219A1 (es) 2002-09-04
EP1169005A2 (fr) 2002-01-09

Similar Documents

Publication Publication Date Title
EP1383743A4 (en) DOUBLE INHIBITORS OF PDE 7 AND PDE 4
SI1341769T1 (sl) Inhibitorji bakterijske giraze in njihove uporabe
NO20014823D0 (no) Heterocyklus-holdige bifenyl-aP2-inhibitorer og metode
IS6385A (is) Ný notkun og nýjar N-asabísýkló-amíð afleiður
SI1251848T1 (en) Gyrase inhibitors and uses thereof
IL149118A0 (en) Inhibitors of neuraminidases
PL375877A1 (en) Hydantoine derivatives and their use as tace inhibitors
NO20030725D0 (no) Terapeutisk kombinasjon av CETP-inhibitor og atorvastatin
EP1474445A4 (en) ADIPONECTIN GLYCO-ISOFORMS, AND USES THEREOF
HUP0304052A3 (en) Heterocyclic inhibitors of erk2 and uses thereof
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
NO20013393D0 (no) Brönnsementeringsfremgangsmåter og sammensetninger
IL152078A0 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
NO20001323D0 (no) Dipeptid-apoptose inhibitorer og deres anvendelse
NO20015274L (no) ACE-2 inhiberende forbindelser og fremgangsmåter for anvendelse derav
NO20032441D0 (no) Kombinasjon av GABA agonister og sorbitol-dehydrogenase inhibitorer
NO331215B1 (no) Kit av deler og farmasoytiske formuleringer
AU2003239544A1 (en) Amplification and overexpression of oncogenes
NO20014770L (no) Assosiasjon av NO-syntase-inhibitor(er) og metabolske antioksydanter
EP1085872A4 (en) TRANSCRIPTION FACTOR NF- $ g (k) B INHIBITORS
NO20020326L (no) Sammensetning og anvendelse av en inhibitor av PPAR-delta-aktivitet
IL131047A0 (en) Use of il-18 inhibitors
AU2003254064A8 (en) Amplification and overexpression of oncogenes
AU2003285686A8 (en) Glycoisoforms of adiponectin and uses thereof
DK1228026T3 (da) 15-Hydroxyicosatetraensyrerelaterede forbindelser og fremgangsmåde til anvendelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application